...
首页> 外文期刊>The Journal of Thoracic and Cardiovascular Surgery >Impact on outcomes after listing and transplantation, of a strategy to accept ABO blood group-incompatible donor hearts for neonates and infants.
【24h】

Impact on outcomes after listing and transplantation, of a strategy to accept ABO blood group-incompatible donor hearts for neonates and infants.

机译:列出和移植后接受新生儿和婴儿ABO血型不相容供体心脏的策略对结局的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Recent data suggest that ABO blood group-incompatible donor hearts are immunologically well tolerated in infants undergoing transplantation. METHODS: Competing-risks methodology was used to assess outcomes after listing and the impact of a strategy to accept heart grafts from any blood group donor for infants less than 18 months of age. RESULTS: From 1992 to 2002, there were 91 listing episodes in 84 patients (including 20 fetuses; 50% were male and 63% had congenital heart disease). Beginning in 1995, a strategy to accept ABO-incompatible organs was adopted. Competing-risks analysis showed that after 20 months 60% underwent transplantation, 18% died, and less than 1% were still listed; the remaining 21% were de-listed because of a change of surgical strategy (9%), improved clinical condition (8%), and deterioration to ineligibility (4%). Risk factors for transplantation included only a strategy to accept ABO-incompatible organs (P <.001). Risk factors for death included failure to accept ABO-incompatible organs (P =.002) and Canadian listing status 3 (P =.085) or 4 (P <.001). Multivariable parametric models were used to create competing risk predictions for outcomes specific to status and ABO-incompatible strategy. Higher status resulted in greater mortality regardless of strategy, although for any status, more patients underwent transplantation and fewer died using a strategy to accept ABO-incompatible organs. Parametric modeling of time-related freedom from death or retransplantation demonstrated no significant difference at 4 years posttransplantation (P =.78) for ABO-incompatible (74%) versus ABO-compatible transplants (72%). CONCLUSIONS: A strategy to accept ABO-incompatible donor hearts for infant transplantation significantly improves the likelihood of transplantation and reduces waiting list mortality while not adversely altering outcomes after transplantation.
机译:背景:最新数据表明,在接受移植的婴儿中,ABO血型不相容的供体心脏在免疫学上耐受良好。方法:采用竞争风险方法评估上市后的结局,以及接受任何血型供体的未满18个月婴儿接受心脏移植的策略的影响。结果:从1992年到2002年,在84例患者中有91例发作事件(包括20例胎儿;男性50%,先天性心脏病63%)。从1995年开始,采用了接受ABO不相容器官的策略。竞争风险分析显示,移植20个月后,有60%的患者接受了移植,死亡的有18%,仍然不到1%。其余21%的患者因手术策略改变(9%),临床状况改善(8%)和不合格情况恶化(4%)而被除名。移植的危险因素仅包括接受ABO不相容器官的策略(P <.001)。死亡的危险因素包括未能接受与ABO不相容的器官(P = .002)和加拿大上市状态3(P = .085)或4(P <.001)。多变量参数模型用于为状态和ABO不兼容策略特有的结果创建竞争性风险预测。无论采用哪种策略,较高的状态都会导致更高的死亡率,尽管对于任何状态,使用接受ABO不相容器官的策略,都会有更多的患者进行移植,而死亡的人数则更少。与时间相关的免于死亡或再移植的自由度的参数化模型显示,与ABO兼容的移植(72%)与ABO兼容的移植(74%)在移植后4年(P = .78)无显着差异。结论:接受不兼容ABO的供体心脏进行婴儿移植的策略可显着提高移植的可能性并降低等待名单的死亡率,同时不会不利地改变移植后的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号